Development of an aciclovir implant for the effective long-term control of herpes simplex virus type-1 infection in Vero cells and in experimentally infected SKH-1 mice

Tory Johnson, Robin Frey, Melissa Modugno, Timothy P. Brennan, Barry J. Margulies

Research output: Contribution to journalArticle

Abstract

Human herpes simplex virus type-1 (HSV-1) is treatable with oral doses of an antiviral agent such as aciclovir (ACV), a drug that has poor bioavailability. An alternative for delivering ACV would employ a long-lived subcutaneous implant that would allow for near zero-order drug delivery kinetics. This study aimed to develop an implant composed of a matrix of silicone and ACV that is capable of sustained long-term release of ACV. Once the implants had been created, release of ACV from the implants was determined and quantified in vitro using a spectrophotometric assay for the drug. Solvent-exposed surface area of the implant (2.86 mm2, 6.28 mm2, 34.62 mm2 and 100.48 mm2) had a significant effect on release kinetics, whereas temperature (37 °C, 25 °C and 4 °C) and pH (6.0, 7.0 and 8.0) did not. The implants were also used successfully to suppress HSV-1 (KOS)-induced cytopathic effect in cultured Vero cells. The implants protected HSV-1-infected SKH-1 mice from viral reactivation (n = 37; P = 0.0367) via ultraviolet light compared with mice that were untreated (n = 37). Furthermore, mice that received silicone-only implants had no lowered risk of reactivation (n = 34; P = 0.7268), demonstrating the antiviral efficacy of the ACV implants.

Original languageEnglish (US)
Pages (from-to)428-435
Number of pages8
JournalInternational Journal of Antimicrobial Agents
Volume30
Issue number5
DOIs
StatePublished - Nov 2007
Externally publishedYes

Fingerprint

Vero Cells
Acyclovir
Human Herpesvirus 1
Virus Diseases
Silicones
Antiviral Agents
Ultraviolet Rays
Pharmaceutical Preparations
Biological Availability
Cultured Cells
Pharmacokinetics
Temperature

Keywords

  • Aciclovir
  • Controlled release
  • Herpes simplex
  • Murine model
  • Recrudescence
  • Silicone
  • Vero

ASJC Scopus subject areas

  • Applied Microbiology and Biotechnology
  • Microbiology
  • Parasitology
  • Virology
  • Immunology and Allergy
  • Infectious Diseases

Cite this

Development of an aciclovir implant for the effective long-term control of herpes simplex virus type-1 infection in Vero cells and in experimentally infected SKH-1 mice. / Johnson, Tory; Frey, Robin; Modugno, Melissa; Brennan, Timothy P.; Margulies, Barry J.

In: International Journal of Antimicrobial Agents, Vol. 30, No. 5, 11.2007, p. 428-435.

Research output: Contribution to journalArticle

@article{727d7c4aa4fb4c14b6aea354d9bde9f7,
title = "Development of an aciclovir implant for the effective long-term control of herpes simplex virus type-1 infection in Vero cells and in experimentally infected SKH-1 mice",
abstract = "Human herpes simplex virus type-1 (HSV-1) is treatable with oral doses of an antiviral agent such as aciclovir (ACV), a drug that has poor bioavailability. An alternative for delivering ACV would employ a long-lived subcutaneous implant that would allow for near zero-order drug delivery kinetics. This study aimed to develop an implant composed of a matrix of silicone and ACV that is capable of sustained long-term release of ACV. Once the implants had been created, release of ACV from the implants was determined and quantified in vitro using a spectrophotometric assay for the drug. Solvent-exposed surface area of the implant (2.86 mm2, 6.28 mm2, 34.62 mm2 and 100.48 mm2) had a significant effect on release kinetics, whereas temperature (37 °C, 25 °C and 4 °C) and pH (6.0, 7.0 and 8.0) did not. The implants were also used successfully to suppress HSV-1 (KOS)-induced cytopathic effect in cultured Vero cells. The implants protected HSV-1-infected SKH-1 mice from viral reactivation (n = 37; P = 0.0367) via ultraviolet light compared with mice that were untreated (n = 37). Furthermore, mice that received silicone-only implants had no lowered risk of reactivation (n = 34; P = 0.7268), demonstrating the antiviral efficacy of the ACV implants.",
keywords = "Aciclovir, Controlled release, Herpes simplex, Murine model, Recrudescence, Silicone, Vero",
author = "Tory Johnson and Robin Frey and Melissa Modugno and Brennan, {Timothy P.} and Margulies, {Barry J.}",
year = "2007",
month = "11",
doi = "10.1016/j.ijantimicag.2007.07.003",
language = "English (US)",
volume = "30",
pages = "428--435",
journal = "International Journal of Antimicrobial Agents",
issn = "0924-8579",
publisher = "Elsevier",
number = "5",

}

TY - JOUR

T1 - Development of an aciclovir implant for the effective long-term control of herpes simplex virus type-1 infection in Vero cells and in experimentally infected SKH-1 mice

AU - Johnson, Tory

AU - Frey, Robin

AU - Modugno, Melissa

AU - Brennan, Timothy P.

AU - Margulies, Barry J.

PY - 2007/11

Y1 - 2007/11

N2 - Human herpes simplex virus type-1 (HSV-1) is treatable with oral doses of an antiviral agent such as aciclovir (ACV), a drug that has poor bioavailability. An alternative for delivering ACV would employ a long-lived subcutaneous implant that would allow for near zero-order drug delivery kinetics. This study aimed to develop an implant composed of a matrix of silicone and ACV that is capable of sustained long-term release of ACV. Once the implants had been created, release of ACV from the implants was determined and quantified in vitro using a spectrophotometric assay for the drug. Solvent-exposed surface area of the implant (2.86 mm2, 6.28 mm2, 34.62 mm2 and 100.48 mm2) had a significant effect on release kinetics, whereas temperature (37 °C, 25 °C and 4 °C) and pH (6.0, 7.0 and 8.0) did not. The implants were also used successfully to suppress HSV-1 (KOS)-induced cytopathic effect in cultured Vero cells. The implants protected HSV-1-infected SKH-1 mice from viral reactivation (n = 37; P = 0.0367) via ultraviolet light compared with mice that were untreated (n = 37). Furthermore, mice that received silicone-only implants had no lowered risk of reactivation (n = 34; P = 0.7268), demonstrating the antiviral efficacy of the ACV implants.

AB - Human herpes simplex virus type-1 (HSV-1) is treatable with oral doses of an antiviral agent such as aciclovir (ACV), a drug that has poor bioavailability. An alternative for delivering ACV would employ a long-lived subcutaneous implant that would allow for near zero-order drug delivery kinetics. This study aimed to develop an implant composed of a matrix of silicone and ACV that is capable of sustained long-term release of ACV. Once the implants had been created, release of ACV from the implants was determined and quantified in vitro using a spectrophotometric assay for the drug. Solvent-exposed surface area of the implant (2.86 mm2, 6.28 mm2, 34.62 mm2 and 100.48 mm2) had a significant effect on release kinetics, whereas temperature (37 °C, 25 °C and 4 °C) and pH (6.0, 7.0 and 8.0) did not. The implants were also used successfully to suppress HSV-1 (KOS)-induced cytopathic effect in cultured Vero cells. The implants protected HSV-1-infected SKH-1 mice from viral reactivation (n = 37; P = 0.0367) via ultraviolet light compared with mice that were untreated (n = 37). Furthermore, mice that received silicone-only implants had no lowered risk of reactivation (n = 34; P = 0.7268), demonstrating the antiviral efficacy of the ACV implants.

KW - Aciclovir

KW - Controlled release

KW - Herpes simplex

KW - Murine model

KW - Recrudescence

KW - Silicone

KW - Vero

UR - http://www.scopus.com/inward/record.url?scp=34848870564&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34848870564&partnerID=8YFLogxK

U2 - 10.1016/j.ijantimicag.2007.07.003

DO - 10.1016/j.ijantimicag.2007.07.003

M3 - Article

C2 - 17851051

AN - SCOPUS:34848870564

VL - 30

SP - 428

EP - 435

JO - International Journal of Antimicrobial Agents

JF - International Journal of Antimicrobial Agents

SN - 0924-8579

IS - 5

ER -